Guided Therapeutics INC Form 4 insider transactions

Director Richard P. Blumberg significantly increased his common stock holdings in Guided Therapeutics through warrant exercises and preferred stock conversions.

Director Alan Grujic acquired 110,000 stock options for Guided Therapeutics Inc. (GTHP) with an exercise price of $0.29, vesting over several years.

John E. Imhoff, a Director and 10% owner of Guided Therapeutics Inc., reported several transactions including stock option exercises and convertible note conversions.

Guided Therapeutics Inc. reports that Director James Michael C acquired stock options for 110,000 shares, with vesting scheduled through March 2029.

GUIDED THERAPEUTICS Director John E. Imhoff significantly increased his beneficial ownership in the company through multiple conversions of debt and preferred stock into common shares and warrant exercises.

GUIDED THERAPEUTICS Director Michael C. James increased his direct ownership of common stock and extended the expiration of other warrants through recent transactions.

GUIDED THERAPEUTICS Director Alan Grujic increased his beneficial ownership of common stock and warrants through dividend payments, preferred stock conversion, and private financing.

GUIDED THERAPEUTICS Director John E. Imhoff significantly increased his beneficial ownership through preferred stock conversions, dividend payments, and a direct purchase of common stock and warrants.

A director and 10% owner of Guided Therapeutics Inc. significantly increased common stock holdings through preferred stock dividend conversions and a direct preferred stock conversion, alongside receiving new stock options.

Guided Therapeutics Director Michael C. James acquired additional common stock and warrants, increasing his beneficial ownership in the company.

GUIDED THERAPEUTICS INC Director Michael C. James has reported the acquisition of 110,000 stock options with a vesting schedule extending to June 2028.

Alan Grujic, a Director at GUIDED THERAPEUTICS INC, has acquired 110,000 stock options with an exercise price of $0.14, vesting over a period until June 2028.

John E. Imhoff, a Director of Guided Therapeutics Inc., was granted 110,000 stock options with an exercise price of $0.14, vesting over time until June 2028.

John E. Imhoff, a Director and 10% Owner of Guided Therapeutics Inc. (GTHP), reported a substantial increase in his direct beneficial ownership of common stock through a series of preferred stock conversions and new acquisitions in March and April 2025.

John E. Imhoff, a director and 10% owner of Guided Therapeutics, reports a series of transactions involving preferred and common stock, including conversions, purchases, and exchanges.

Michael C. James, a director of Guided Therapeutics, acquired shares and warrants through a securities purchase agreement and an exchange agreement.

Director John E. Imhoff acquired 35,312 shares of Guided Therapeutics Inc. common stock through the conversion of accrued dividends on Series D preferred stock.

A Guided Therapeutics director, John E. Imhoff, acquired 1,615,385 shares and warrants for the same amount of shares at an exercise price of $0.18 per share, in a transaction valued at $210,000.

John E. Imhoff, a director and 10% owner of Guided Therapeutics, acquired 36,161 shares of common stock through the conversion of accrued dividends on Series D preferred stock.

Richard Blumberg, a director and 10% owner of Guided Therapeutics Inc., reports the acquisition of common stock and warrants related to a consulting agreement.

John E. Imhoff, a director and 10% owner of Guided Therapeutics, acquired 1,666,667 shares of common stock and warrants to purchase an additional 1,666,667 shares for $150,000.

Director Michael C. James of Guided Therapeutics Inc. reports acquisition of stock options and warrants, alongside the disposal of warrants.

Director John E. Imhoff reports the acquisition of stock options and warrants in Guided Therapeutics Inc.

Richard P. Blumberg, a director and 10% owner of Guided Therapeutics Inc., acquired stock options on July 9, 2024.

Alan Grujic, a director of Guided Therapeutics Inc., reports transactions involving stock options and warrants.

Director Alan Grujic acquired 36,602 shares of Guided Therapeutics Inc. common stock due to accrued dividends on Series E preferred stock.

Director John E. Imhoff acquired 183,008 shares of Guided Therapeutics Inc. common stock through the conversion of accrued dividends on Series E preferred stock.

Richard P. Blumberg, a director of Guided Therapeutics Inc., acquired 170,563 shares of common stock through the conversion of accrued dividends on Series E preferred stock.

Director John E. Imhoff acquired 48,327 shares of Guided Therapeutics Inc. common stock through the conversion of accrued dividends on Series D preferred stock.

Director John E. Imhoff increased his holdings in Guided Therapeutics through the conversion of accrued dividends from Series F and Series D preferred stock into common stock.